Outlook Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell OTLK and other ETFs, options, and stocks.About OTLK
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF.
CEORobert Charles Jahr
CEORobert Charles Jahr
Employees17
Employees17
HeadquartersIselin, New Jersey
HeadquartersIselin, New Jersey
Founded2010
Founded2010
Employees17
Employees17
OTLK Key Statistics
Market cap32.78M
Market cap32.78M
Price-Earnings ratio-0.32
Price-Earnings ratio-0.32
Dividend yield—
Dividend yield—
Average volume1.35M
Average volume1.35M
High today$0.4282
High today$0.4282
Low today$0.3602
Low today$0.3602
Open price$0.379
Open price$0.379
Volume1.74M
Volume1.74M
52 Week high$3.39
52 Week high$3.39
52 Week low$0.3418
52 Week low$0.3418
Stock Snapshot
Outlook Therapeutics(OTLK) stock is priced at $0.39, giving the company a market capitalization of 32.78M. It carries a P/E multiple of -0.32.
During the trading session on 2026-03-17, Outlook Therapeutics(OTLK) shares reached a daily high of $0.43 and a low of $0.36. At a current price of $0.39, the stock is +7.5% higher than the low and still -9.6% under the high.
Trading volume for Outlook Therapeutics(OTLK) stock has reached 1.74M, versus its average volume of 1.35M.
Over the past 52 weeks, Outlook Therapeutics(OTLK) stock has traded between a high of $3.39 and a low of $0.34.
Over the past 52 weeks, Outlook Therapeutics(OTLK) stock has traded between a high of $3.39 and a low of $0.34.
People also own
Based on the portfolios of people who own OTLK. This list is generated using Robinhood data, and it’s not a recommendation.